June 14, 2021 -- Synthetic biology firm AbSci has acquired human immune response discovery company Totient. The deal adds antibody and therapeutic target technology to AbSci's range of offerings.
Totient has expertise in identifying human antibodies in patients with different immune responses; it has reconstructed more than 4,500 antibodies from over 50,000 patients, AbSci said. The company hopes to develop natural human antibodies and target antigens using this expertise and to establish training sets for its Denovium Engine deep-learning model.